Collectively, these results indicate that targeting the PLK1/STAT3 axis not only enhances the therapeutic efficacy of EGFR/MEK/ERK pathway inhibitors but also represents a promising strategy to delay and overcome resistance in EGFR-mutant NSCLC. Here, MAP2K7 is linked to non-small cell lung carcinoma.